About Us
Management
Milestones
Culture
Contact Us
2016
Enable some production of affiliates of relocation, the expansion of the work And the raw materials and preparations of Hainan simcere get the EU cGMP certification again.
2015
The strategic cooperation agreement with Daiichi Sankyo Co. Ltd. was concluded, for jointly forming hypertension compound brand - OLMETEC®
2014
The entrepreneurial community -“BioSciKin”was put into use;
2013
Orencia of BMS used for rheumatoid arthritis was developed and commercialized with BMS in China;
2012
The State Category1.1 New Drug- Iremod®(Iguratimod Tablets) researched and developed independently was listed;
2011
Simcere pharmaceutical R&D lab covering 26000 ㎡ has been totally put into use,and EU GMP certificate for Montmorillonite PowderPreparation( Biqi®) was passed;
2010
The EU GMP certificate for active ingredient of Biqi(Montmorillonite Powder) - Montmorillonite raw material was passed, and the certificate was obtained;
With BMS announced a strategic cooperative relations, and develop antitumor drugs BMS - 817378;
2009
Agreement between Simcere and other famous companies such as American Epitomics, OSI, etc. was concluded, in order to develop many international innovative drugs jointly;
2008
The domestic firstly listed brand medicines such as Sinofuan®(Fluorouracil Implants) ,Jiebaishu®(Nedaplatin for Injection), Newanti® (Biapenem for Injection), etc. were successively launched, and the enterprise development strategy was further carried out;
2007
Simcere entered the largest capital market in the world-NYSE, with the stock code “SCR”;
2006
Simcere merged 80% of share of Yantai Medgenn Co., Ltd., and the State Category Ⅰ New Drug of antineoplastic - ENDOSTAR was officially listed, entering field of tumor treatment;
2005
HONY CAPITAL under Legend holdings was introduced as strategic investor;
2004
BICUN®(Edaravone Injection) was successfully researched and developed firstly throughout the country and secondly in the world;
2003
Simcere Group and Simcere Drug Research Institute were officially formed;
2000
Simcere New Drugs Research Center was founded, and firstly started R&D ofBICUN®(Edaravone Injection) domestically;
1999
Jiangsu Cuccess Pharma. was renamed as Simcere;
1996-98
Jiangsu Cuccess suffered from many setbacks such as disincorporation of enterpreneur team, termination of general dealership requested by partners, etc;
1995
Jiangsu Cuccess Pharmaceutical Co., Ltd. was established, and initially created mode of “General Agency”in the industry;
2016
Enable some production of affiliates of relocation, the expansion of the work And the raw materials and preparations of Hainan simcere get the EU cGMP certification again.
2015
The strategic cooperation agreement with Daiichi Sankyo Co. Ltd. was concluded, for jointly forming hypertension compound brand - OLMETEC®
2014
The entrepreneurial community -“BioSciKin”was put into use;
2013
Orencia of BMS used for rheumatoid arthritis was developed and commercialized with BMS in China;
2012
The State Category1.1 New Drug- Iremod®(Iguratimod Tablets) researched and developed independently was listed;
2011
Simcere pharmaceutical R&D lab covering 26000 ㎡ has been totally put into use,and EU GMP certificate for Montmorillonite PowderPreparation( Biqi®) was passed;
2010
The EU GMP certificate for active ingredient of Biqi(Montmorillonite Powder) - Montmorillonite raw material was passed, and the certificate was obtained;
With BMS announced a strategic cooperative relations, and develop antitumor drugs BMS - 817378;
2009
Agreement between Simcere and other famous companies such as American Epitomics, OSI, etc. was concluded, in order to develop many international innovative drugs jointly;
2008
The domestic firstly listed brand medicines such as Sinofuan®(Fluorouracil Implants) ,Jiebaishu®(Nedaplatin for Injection), Newanti® (Biapenem for Injection), etc. were successively launched, and the enterprise development strategy was further carried out;
2007
Simcere entered the largest capital market in the world-NYSE, with the stock code “SCR”;
2006
Simcere merged 80% of share of Yantai Medgenn Co., Ltd., and the State Category Ⅰ New Drug of antineoplastic - ENDOSTAR was officially listed, entering field of tumor treatment;
2005
HONY CAPITAL under Legend holdings was introduced as strategic investor;
2004
BICUN®(Edaravone Injection) was successfully researched and developed firstly throughout the country and secondly in the world;
2003
Simcere Group and Simcere Drug Research Institute were officially formed;
2000
Simcere New Drugs Research Center was founded, and firstly started R&D ofBICUN®(Edaravone Injection) domestically;
1999
Jiangsu Cuccess Pharma. was renamed as Simcere;
1996-98
Jiangsu Cuccess suffered from many setbacks such as disincorporation of enterpreneur team, termination of general dealership requested by partners, etc;
1995
Jiangsu Cuccess Pharmaceutical Co., Ltd. was established, and initially created mode of “General Agency”in the industry;
© Copyright 2016 www.simcere.com All Rights Reserved.